We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.75 | 8.50 | 9.00 | 8.75 | 8.75 | 8.75 | 6,800 | 07:33:41 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIXI
RNS Number : 3643T
IXICO plc
04 January 2017
4 January 2017
IXICO plc
("IXICO" or the "Company")
Issue of 590,093 Deferred Consideration Shares
IXICO, the brain health company, announces the issue of 590,093 ordinary shares of 1p each as Deferred Consideration in accordance with the terms of the Share Purchase Agreement (the 'Agreement') entered into between the Company and Optimal Medicine Limited on 18 November 2015.
Under the terms of the Agreement, the Deferred Consideration Shares were to be issued on 4 January 2017 following the expiry of the period during which the Company may bring a warranty claim and the determination of the Board of Directors that no such warranty claim is to be made by the Company.
Application has been made for the Deferred Consideration Shares to be admitted to AIM on 9 January 2017. Upon admission of the Deferred Consideration Shares to AIM, the enlarged issued share capital of the Company will be 27,063,284 ordinary shares. The Company does not hold any shares in treasury. Consequently, 27,063,284 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
IXICO plc Tel: +44 20 Derek Hill, Chief Executive Officer 3763 7499 Susan Lowther, Chief Financial Officer Shore Capital (Nomad and Broker) Tel: +44 20 Bidhi Bhoma / Edward Mansfield 7408 4090 FTI Consulting Limited (Investor Tel: +44 20 Relations) 3727 1000 Simon Conway/Mo Noonan/Matthew Moss
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEZLFBDFFXBBK
(END) Dow Jones Newswires
January 04, 2017 10:43 ET (15:43 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions